retatrutide

Online-bought retatrutide, a hospital admission, and the limits of a single case

by
Online-bought retatrutide, a hospital admission, and the limits of a single case

A case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also … Read more

Retatrutide met its endpoints in two more Phase 3 trials, but not on cardiovascular events

by
Retatrutide met its endpoints in two more Phase 3 trials, but not on cardiovascular events

Eli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up … Read more